Flonase Allergy Relief

House dust allergy, Sneezing, Allergic Rhinitis + 22 more

Treatment

20 Active Studies for Flonase Allergy Relief

Treatment for

House dust allergy

What is Flonase Allergy Relief

Fluticasone propionate

The Generic name of this drug

Treatment Summary

Fluticasone propionate is a type of steroid medication used to reduce inflammation. It is available in the form of inhalers, nasal sprays, and topical treatments. Fluticasone propionate was approved by the FDA in 1990 and is mainly used to treat inflammatory conditions.

Cutivate

is the brand name

image of different drug pills on a surface

Flonase Allergy Relief Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cutivate

Fluticasone propionate

1990

366

Effectiveness

How Flonase Allergy Relief Affects Patients

Fluticasone propionate affects the body by activating certain receptors and reducing eosinophilia, an increase in white blood cells, in the lungs. When applied to the skin, it can cause the blood vessels to narrow.

How Flonase Allergy Relief works in the body

Fluticasone propionate works in an unknown way to reduce inflammation in the lungs. It does this by activating certain receptors in the body, which then stop swelling and other inflammation-related reactions.

When to interrupt dosage

The endorsed dosage of Flonase Allergy Relief is contingent upon the determined condition, including Sinusitis, Chronic Obstructive Pulmonary Disease (COPD) and Non-Allergic Rhinitis. The precise dosage is contingent upon the method of administration (e.g. Spray, metered - Nasal or Respiratory (inhalation)) specified in the table beneath.

Condition

Dosage

Administration

prophylaxis of Allergic rhinitis

, 0.05 mg, 0.0005 mg/mg, 0.00005 mg/mg, 0.25 mg, 0.1 mg, 0.5 mg, 0.044 mg, 0.11 mg, 0.22 mg, 0.5 mg/mL, 0.05 %, 0.045 mg, 0.115 mg, 0.23 mg, 0.055 mg, 0.113 mg, 0.232 mg, 0.093 mg, 5.0 mg/mg, 2.5 mg/mg, 0.1 mg/pump actuation, 0.055 mg/pump actuation, 0.25 mg/pump actuation, 0.5 mg/pump actuation, 0.125 mg/pump actuation, 0.05 mg/pump actuation, 0.113 mg/pump actuation, 0.025 mg/pump actuation, 0.232 mg/pump actuation, 0.202 mg

, Nasal, Spray, metered, Spray, metered - Nasal, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Respiratory (inhalation), Powder, metered - Respiratory (inhalation), Powder, metered, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Lotion - Topical, Lotion, Powder - Oral; Respiratory (inhalation), Oral; Respiratory (inhalation), Kit, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Kit - Topical, Spray, Spray - Nasal, Kit - Nasal

Bronchitis, Chronic

Eosinophilic Esophagitis

Allergy to Mold

Sinusitis

Nasal Congestion

Nose

Rhinitis

House dust allergy

Emphysema

Rhinorrhea

Hay Fever

Sinusitis

Adrenal Cortex Hormones

moderate, severe Seasonal Allergic Rhinitis

Asthma

Chronic Obstructive Pulmonary Disease

Allergy to Tree Pollen

Rhinitis, Allergic

Allergy to Animal Dander

Warnings

Flonase Allergy Relief has five contraindications and should not be administered in the presence of the ailments delineated in the following table.

Flonase Allergy Relief Contraindications

Condition

Risk Level

Notes

Status Asthmaticus

Do Not Combine

Asthma

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluticasone Propionate may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Fluticasone Propionate may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Fluticasone Propionate may interact with Pulse Frequency

There are 20 known major drug interactions with Flonase Allergy Relief.

Common Flonase Allergy Relief Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Fluticasone propionate.

Abetimus

Major

The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Abetimus.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Fluticasone propionate.

Flonase Allergy Relief Toxicity & Overdose Risk

The effects of taking fluticasone propionate have not been studied in certain population groups. In animal studies, subcutaneous administration has been linked to birth defects in rats, but taking it orally does not carry the same risk. There is no evidence that fluticasone has any adverse effects during pregnancy. The drug may affect growth and natural steroid production in infants whose mothers are taking fluticasone, so caution should be used in breastfeeding. Elderly patients may be more sensitive to the side effects of fluticasone, and those with liver disease should be monitored closely. Fluticasone propionate does not

image of a doctor in a lab doing drug, clinical research

Flonase Allergy Relief Novel Uses: Which Conditions Have a Clinical Trial Featuring Flonase Allergy Relief?

389 active trials are currently assessing the capacity of Flonase Allergy Relief to alleviate Nasal Congestion, House Dust Mite Allergy and Atopic Dermatitis.

Condition

Clinical Trials

Trial Phases

Bronchitis, Chronic

0 Actively Recruiting

Asthma

92 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

Chronic Obstructive Pulmonary Disease

76 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Sinusitis

0 Actively Recruiting

Adrenal Cortex Hormones

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Sinusitis

6 Actively Recruiting

Early Phase 1, Phase 2, Phase 3, Phase 1

House dust allergy

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Allergy to Mold

0 Actively Recruiting

Allergy to Tree Pollen

0 Actively Recruiting

Allergic Rhinitis

0 Actively Recruiting

Nose

0 Actively Recruiting

Eosinophilic Esophagitis

0 Actively Recruiting

moderate, severe Seasonal Allergic Rhinitis

0 Actively Recruiting

Sneezing

0 Actively Recruiting

Hay Fever

0 Actively Recruiting

House Dust Mite Allergy

0 Actively Recruiting

Non-Allergic Rhinitis

0 Actively Recruiting

Atopic Dermatitis

10 Actively Recruiting

Phase 2, Phase 3, Phase 4

Patient Q&A Section about flonase allergy relief

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is FLONASE a steroid or antihistamine?

"Fluticasone (Flonase) is a type of steroid that helps to lessen the inflammation caused by allergies, but it is neither an antihistamine or decongestant."

Answered by AI

What allergy symptoms does FLONASE relieve?

"Fluticasone nasal spray is available without a prescription and can be used to relieve symptoms of rhinitis such as sneezing, a stuffy or itchy nose, and itchy, watery eyes caused by hay fever or other allergies."

Answered by AI

How long does it take FLONASE to work for allergies?

"How soon does Flonase allergy relief take effect? Many people start to feel relief after the first day, with full effectiveness usually after three or four days of regular, once-a-day use. That's why it's recommended that you use Flonase every day."

Answered by AI

Does FLONASE relieve allergies?

"FLONASE SENSIMIST and FLONASE Allergy Relief are both prescription allergy medicines that provide 24-hour relief from your allergy symptoms.Both work in your nose to relieve your allergy symptoms—sneezing, itchy nose, runny nose, itchy, watery eyes*, and nasal congestion."

Answered by AI

Clinical Trials for Flonase Allergy Relief

Have you considered Flonase Allergy Relief clinical trials?

We made a collection of clinical trials featuring Flonase Allergy Relief, we think they might fit your search criteria.

Explore trials for Flonase Allergy Relief

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions